Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP. Swiecicki PL, et al. Among authors: worden fp. Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26. Invest New Drugs. 2016. PMID: 27225873 Free PMC article. Clinical Trial.
Therapeutic advances in small cell lung cancer.
Worden FP, Kalemkerian GP. Worden FP, et al. Expert Opin Investig Drugs. 2000 Mar;9(3):565-79. doi: 10.1517/13543784.9.3.565. Expert Opin Investig Drugs. 2000. PMID: 11060696 Review.
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP, Taylor JM, Biermann JS, Sondak VK, Leu KM, Chugh R, McGinn CJ, Zalupski MM, Baker LH. Worden FP, et al. J Clin Oncol. 2005 Jan 1;23(1):105-12. doi: 10.1200/JCO.2005.05.108. J Clin Oncol. 2005. PMID: 15625365 Clinical Trial.
Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer.
Feng M, Jabbari S, Lin A, Bradford CR, Chepeha DB, Teknos TN, Worden FP, Tsien C, Schipper MJ, Wolf GT, Dawson LA, Eisbruch A. Feng M, et al. Among authors: worden fp. Radiother Oncol. 2005 Oct;77(1):32-8. doi: 10.1016/j.radonc.2005.07.008. Epub 2005 Sep 8. Radiother Oncol. 2005. PMID: 16154219 Clinical Trial.
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH; Southwest Oncology Group, Head and Neck Working Group. Worden FP, et al. Cancer. 2006 Jul 15;107(2):319-27. doi: 10.1002/cncr.21994. Cancer. 2006. PMID: 16779801 Free article. Clinical Trial.
204 results